INKT MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. operates as a clinical stage biopharmaceutical company engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. The company was founded in 2017 and is based in New York, New York.

As of 12/02/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  10/15/2021
Outstanding shares:  33,785,929
Average volume:  54,811
Market cap:   $88,512,377
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLR7FL6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.88
PS ratio:   0.00
Return on equity:   -219,490.58%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy